Takeda Pharmaceutical Co Ltd
XBER:TKD

Watchlist Manager
Takeda Pharmaceutical Co Ltd Logo
Takeda Pharmaceutical Co Ltd
XBER:TKD
Watchlist
Price: 26.05 EUR
Market Cap: €40.9B

Gross Margin

64.6%
Current
Declining
by 2.2%
vs 3-y average of 66.8%

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
64.6%
=
Gross Profit
¥2.9T
/
Revenue
¥4.4T

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
64.6%
=
Gross Profit
€2.9T
/
Revenue
¥4.4T

Peer Comparison

Country Company Market Cap Gross
Margin
JP
Takeda Pharmaceutical Co Ltd
TSE:4502
8T JPY
Loading...
US
Eli Lilly and Co
NYSE:LLY
964.8B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
547.9B USD
Loading...
CH
Roche Holding AG
SIX:ROG
268.4B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
209.9B GBP
Loading...
CH
Novartis AG
SIX:NOVN
219B CHF
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
US
Merck & Co Inc
NYSE:MRK
267.4B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
149.5B USD
Loading...
FR
Sanofi SA
PAR:SAN
94.6B EUR
Loading...

Market Distribution

Higher than 89% of companies in Japan
Percentile
89th
Based on 6 625 companies
89th percentile
64.6%
Low
-179.8% — 21.8%
Typical Range
21.8% — 42.3%
High
42.3% — 18 197.9%
Distribution Statistics
Japan
Min -179.8%
30th Percentile 21.8%
Median 30.6%
70th Percentile 42.3%
Max 18 197.9%

Takeda Pharmaceutical Co Ltd
Glance View

In the ever-evolving landscape of global pharmaceuticals, Takeda Pharmaceutical Co Ltd. stands as a robust and adaptive entity, blending a rich heritage with bold innovation. Originating from Japan, Takeda's journey began over two centuries ago, carving its niche by focusing on value-driven and research-led approaches in the pharmaceutical industry. With its headquarters in Tokyo, the company has fortified its position as one of the global leaders, largely due to its emphasis on research and development that spans across cutting-edge areas such as oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies. This innovation-centric strategy is not just a nod to the future, but a crucial component that allows Takeda to address pressing health challenges worldwide, continually expanding its pipeline with transformative therapies. Takeda's commercial model revolves around its diverse therapeutic portfolio and strategic collaborations, which are instrumental in capturing growth across various markets. By leveraging its scientific expertise and expanding technological capabilities, the company advances its core business segments while integrating augmented biotechnology solutions through strategic acquisitions and partnerships. The absorption of Shire, a prominent biotechnology firm, stands as a hallmark of Takeda's commitment to enhancing its presence in rare diseases and plasma-derived therapies, thereby widening its global footprint. This focus not only fuels revenue generation from innovative products but also ensures a multidimensional approach to market entry across pivotal regions. Through balancing its inventive drive with operational efficiency, Takeda efficiently monetizes its products, securing its status as a formidable player in the pharmaceutical domain.

TKD Intrinsic Value
25.43 EUR
Overvaluation 2%
Intrinsic Value
Price
What is Gross Margin?
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
How is Gross Margin calculated?

Gross Margin is calculated by dividing the Gross Profit by the Revenue.

Gross Margin
64.6%
=
Gross Profit
¥2.9T
/
Revenue
¥4.4T
What is Takeda Pharmaceutical Co Ltd's current Gross Margin?

The current Gross Margin for Takeda Pharmaceutical Co Ltd is 64.6%, which is below its 3-year median of 66.8%.

How has Gross Margin changed over time?

Over the last 3 years, Takeda Pharmaceutical Co Ltd’s Gross Margin has decreased from 68.3% to 64.6%. During this period, it reached a low of 64.6% on Sep 30, 2025 and a high of 69.1% on Mar 31, 2023.

Back to Top